Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. (CRDL) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
crdl · stock forecast · 2 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 2 Wall Street analysts in the past 3 months
Buy
2 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$8.00
Consensus
$8.00
+640.7% upside
Low
$8.00
Median: $8 · Last Close: $1.08
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $1.03 | ↓ 5.00% |
1-day model range: $1.02–$1.03. Peak: $1.03 (-5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $1 | -35.6% |
| 2028 | $1 | -47.1% |
| 2029 | $1 | -51.8% |
| 2030 | $1 | -53.9% |
| 2031 | — | -54.9% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CRDL · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-04-06 | Canaccord Genuity | Maintains | Buy→Buy |
| 2026-02-10 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-12-01 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-04-16 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-04-07 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-02-24 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-18 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-20 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-10-24 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-06-14 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Cardiol Therapeutics Inc. (CRDL) stock. Of the recent 13 rating actions, 0 were upgrades and 0 were downgrades. 2 analysts currently cover CRDL.
Analyst Recommendation Trends
CRDL analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 97.8% YoY
Revenue Next Year
$3M
↑ 194.5% YoY
EPS This Year
$-0.47
EPS Next Year
$-0.22
↓ 52.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast CRDL EPS of $-0.47 for the current fiscal year, based on estimates from 3 analysts. The CRDL revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CRDL stock forecast is supported by two independent data sources: analyst consensus ratings from 2 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CRDL price target is $8.00 (+640.7% upside), with an analyst consensus of Buy.
The CRDL short-term stock prediction for tomorrow is $1.03 (-5.00%). The CRDL stock price prediction for 2027 estimates an average of $1. The CRDL stock prediction for 2030 projects a range of $0–$1.
Cardiol Therapeutics Inc. trades on NASDAQ under the ticker CRDL. The CRDL stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
CRDL forecast · 8 questionsAccording to 2 Wall Street analysts, the average 12-month CRDL price target is $8.00, with a high forecast of $8.00 and a low of $8.00. The median price target is shown in the chart above when available. This implies +640.7% potential upside from the current price of $1.08.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.